PRISM BioLab partners with Receptor.AI for molecule discovery
PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available…
All articles by Salong Debbarma
Salong Debbarma
-
-
PsiQuantum and National Cancer Center Japan partner on quantum computing
PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing…
-
Bavarian Nordic and SII sign agreement for chikungunya vaccine production
Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract…
-
Curatis and Neupharma sign development agreement for corticorelin in Japan
Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema…
-
Idorsia and Pharmalink sign agreement to distribute Quviviq
Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in…
-
FDA approves GSK’s Wellcovorin for cerebral folate deficiency
The US Food and Drug Administration (FDA) has granted its approval for the expanded use of GSK’s Wellcovorin (leucovorin calcium)…
-
Junshi receives China’s NMPA acceptance for toripalimab injection
Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab subcutaneous injection (JS001sc) new drug applications (NDAs)…
-
NewcelX and Eledon partner for NCEL-101 programme
NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D).…
-
Sciwind secures China’s NMPA approval for Ecnoglutide injection
Sciwind Biosciences has received China’s National Medical Products Administration (NMPA) approval for its Ecnoglutide injection for chronic weight management. Ecnoglutide…
-
BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has received the US Food and Drug Administration (FDA) approval for Sotyktu (deucravacitinib), an oral selective…